US EditionTrump Announces Cost Cuts to Weight Loss Drugs
The deal will reduce obesity drug costs to as low as $149 per month and expand Medicare coverage to about 6.6 million beneficiaries, enhancing access to GLP-1 treatments.
- On Thursday, President Donald Trump unveiled a deal with Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for Zepbound and Wegovy, the White House said.
- Rising demand and high cost explain the move as GLP-1 receptor agonists surged in recent years but remained costly, limiting access for American patients, the White House said amid cost-of-living concerns.
- Through TrumpRx, uninsured consumers can buy obesity drugs at reduced prices, with Wegovy dropping to $250, Zepbound to $346, and starting doses at $149 if approved.
- Medicare will expand coverage starting next year, including a Part D pilot covering roughly 6.6 million beneficiaries, while state and federally funded Medicaid programs gain access to lower-priced obesity drugs.
- Experts warned of limits and restrictive eligibility as obesity experts noted state Medicaid variation, the White House tied the deals to MFN policy and tariff relief for three years, while Eli Lilly and Novo Nordisk will extend discounts to future oral GLP-1s.
521 Articles
521 Articles
GLP-1 Costs Are Going Down in 2026—Here’s What to Know
A new deal between the White House and pharmaceutical companies like Novo Nordisk and Eli Lilly is shaking things up.Reviewed by Dietitian Jessica Ball, M.S., RDDesign elements: Getty Images. EatingWell design.Key PointsMonthly GLP-1 costs will drop to $350 or less under TrumpRx starting in 2026.Medicare patients may pay as little as $50/month for Wegovy and Zepbound.GLP-1 drugs are one part of a healthy lifestyle, not a quick fix for weight los…
InsideNoVA.com
Trump Announces Major Price Cut for Ozempic, Wegovy and Similar Drugs
Key Takeaways
Who's eligible and how much will Americans pay in deal for lower weight loss drug prices?
President Trump announced a deal on Thursday that will lower the cost of some weight loss drugs for certain eligible Americans. CBS News medical contributor Dr. Celine Gounder explains the details of the deal and how much Americans can expect to pay.
Trump gets from Novo Nordisk and Eli Lilly a cut in the prices of anti-obesity drugs. While Novo and Pfizer challenge each other for biotech Metsera, in a $10 billion operation
Price cuts help more Americans start weight-loss drugs but maybe not stay on them
By Bhanvi Satija and Chad Terhune LONDON/LOS ANGELES (Reuters) -A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more Americans to give them a try, but the cost may still be too high to keep patients long term, U.S. obesity specialists said. President Donald Trump announced on Thursday that Novo Nordisk would reduce monthly prices for Wegovy to $350. Eli Lilly said Zepbound woul…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
